SK Bioscience reorganizes into 6 divisions... Appoints Kim Jun-mo, former Pfizer executive, as Vice President

Implementation of Organizational Restructuring in 6 Headquarters Units
Kim Jun-mo Appointed New Vice President, Expert in Bio Production and Quality

SK Bioscience has carried out a division-level organizational restructuring and recruited a former Pfizer executive as vice president.

SK Bioscience announced on the 7th that it will implement the organizational restructuring effective from the 13th. Through this restructuring, the existing organization will be reorganized into six division-level units: ▲Business Development (BD) Division ▲Bio Research Division ▲Development Division ▲L HOUSE Factory ▲Quality Division ▲Management Support Division. Based on this, SK Bioscience plans to transition each division to a responsibility management system and focus on business advancement and strengthening expertise.

With this restructuring, the six divisions will each perform specialized functions. The BD Division will handle tasks such as business portfolio management and establishing overseas partnerships. The Bio Research Division will be responsible for advancing the product portfolio to a global standard. The Development Division will promote clinical trials, development, and approvals during the research and development (R&D) process, while the L HOUSE and Quality Divisions will manage the production of commercial products and global-level quality control. The Management Support Division will oversee company-wide strategy, new business development and investment, and finance.

Along with the organizational restructuring, SK Bioscience established a Quality Excellence (QE) Office within the Quality Division, which was previously composed of Quality Control (QC) and Quality Assurance (QA), to enhance competitiveness. The QE Office will lead quality advancement efforts to elevate the product manufacturing processes at the Andong L HOUSE vaccine factory and the Songdo Global R&PD Center, scheduled for completion in 2025, to meet the U.S. current Good Manufacturing Practice (cGMP) standards.

Kim Jun-mo, a former Pfizer executive, was recruited as vice president to lead the newly established QE Office. Vice President Kim worked on product process management at Pfizer in the U.S. Additionally, SK Bioscience explained that he is an expert who has led production and quality advancement at global bio companies for over 20 years, including roles such as Pfizer quality investigation lead for APEC Singapore and operations director at Legend Biotech, a biotechnology company located in New Jersey, USA.

SK Bioscience President Ahn Jae-yong said, "This organizational restructuring is intended to respond swiftly to the rapidly changing business environment and strengthen internal capabilities in each area to secure clear competitiveness." He added, "By reinforcing responsibility management, we will achieve the company’s mid- to long-term growth strategy and further leap forward as an innovative vaccine and bio company."